{"ticker": {"uuid": "c6c024d9-f6de-4dd3-8d61-dc686f28f5b9", "symbol": "SKYE", "name": "Skye Bioscience, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-16T05:52:27+00:00", "published_display": "16 Jul 2026 05:52", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Skye Bioscience, Inc. Financial Disclosures & SEC Filings", "summary": "This page provides a comprehensive list of Skye Bioscience, Inc.'s SEC filings and other crucial corporate documents, including annual and quarterly reports, earnings releases, and corporate presentations. These documents outline the company's financial performance, operational u", "url": "https://www.tradingview.com/symbols/BOATS-SKYE/documents/", "source_name": "TradingView", "published_at": "2026-07-01T13:42:07", "published_display": "01 Jul 2026 13:42", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Skye Bioscience, Inc. (NASDAQ: SKYE) on behalf of investors who purchased securities before November 4, 2024, and still hold them. The investigation seeks to determine if Skye and its officers engaged in", "url": "https://natlawreview.com/press-releases/skye-bioscience-inc-skye-investigation-bronstein-gewirtz-grossman-llc-1", "source_name": "The National Law Review", "published_at": "2026-06-30T18:39:43", "published_display": "30 Jun 2026 18:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Skye Bioscience, Inc. \u2013 NASDAQ:SKYE", "summary": "This article provides financial information for Skye Bioscience, Inc. (NASDAQ: SKYE), specifically focusing on its forward price-to-sales ratio. The content appears to be a market data page from TradingView, offering an overview of the company's financials for investors and analy", "url": "https://www.tradingview.com/symbols/NASDAQ-SKYE/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T19:09:45", "published_display": "27 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Skye Bioscience, Inc. \u2013 NASDAQ:SKYE", "summary": "This article provides the \"Price to earnings forward\" metric for Skye Bioscience, Inc. (NASDAQ: SKYE) as displayed on TradingView. It notes that the market is closed and no trades have occurred for this specific metric. The content primarily consists of navigation and disclaimer ", "url": "https://www.tradingview.com/symbols/NASDAQ-SKYE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:40:18", "published_display": "27 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Skye Bioscience, Inc. \u2013 NASDAQ:SKYE", "summary": "This article provides financial information for Skye Bioscience, Inc. (NASDAQ: SKYE), specifically focusing on its \"Price to book forward\" metric. It appears to be a stub or an incomplete financial data page from TradingView, lacking specific numerical data for the metric but ind", "url": "https://www.tradingview.com/symbols/NASDAQ-SKYE/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:39:46", "published_display": "27 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience, Inc. Actuals & Estimates (FWB:09R)", "summary": "This article provides financial actuals and estimates for Skye Bioscience, Inc. (FWB:09R), covering income statement, balance sheet, cash flow, and valuation metrics. It includes analyst price targets, historical stock performance, earnings reports, and other key financial data. ", "url": "https://www.tradingview.com/symbols/FWB-09R/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T04:11:09", "published_display": "26 Jun 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SKYE Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast for Skye Bioscience, Inc. (SKYE) stock, including analyst price targets, current stock performance, and financial data. It notes that analysts have a max estimated price target of $20.00 and a min of $2.00, while the stock has seen significant decr", "url": "https://www.tradingview.com/symbols/NASDAQ-SKYE/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T15:10:25", "published_display": "25 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience Moves Listing to Nasdaq Capital Market", "summary": "Skye Bioscience (SKYE) has transferred its listing from the Nasdaq Global Market to the Nasdaq Capital Market due to its stockholders' equity falling below the $10 million threshold. The company also faces a compliance issue with Nasdaq's $1.00 minimum bid price rule and has unti", "url": "https://www.theglobeandmail.com/investing/markets/stocks/SKYE/pressreleases/2622086/skye-bioscience-moves-listing-to-nasdaq-capital-market/", "source_name": "The Globe and Mail", "published_at": "2026-06-25T06:09:16", "published_display": "25 Jun 2026 06:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience to Move Listing to Nasdaq Capital Market After Equity Shortfall", "summary": "Skye Bioscience (SKYE) will transfer its common stock listing to the Nasdaq Capital Market, effective June 23, 2026, after its stockholders' equity fell below the Nasdaq Global Market's $10 million requirement. The company reported $9,011,804 in equity as of March 31, 2026. Skye ", "url": "https://www.tradingview.com/news/tradingview:cac6ae3dbb208:0-skye-bioscience-to-move-listing-to-nasdaq-capital-market-after-equity-shortfall/", "source_name": "TradingView", "published_at": "2026-06-23T10:10:25", "published_display": "23 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience (NASDAQ: SKYE) shifts to Nasdaq Capital Market amid listing notices", "summary": "Skye Bioscience is transferring its common stock listing from the Nasdaq Global Market to the Nasdaq Capital Market, effective June 23, 2026, due to non-compliance with the Global Market's minimum stockholders' equity requirement. The company's ticker symbol will remain \"SKYE.\" A", "url": "https://www.stocktitan.net/sec-filings/SKYE/8-k-skye-bioscience-inc-reports-material-event-4999aded00db.html", "source_name": "Stock Titan", "published_at": "2026-06-22T22:10:25", "published_display": "22 Jun 2026 22:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience, Inc. Stock 12\u2011Month Price Target Cut to $7.33, Implies 937% Upside", "summary": "Skye Bioscience, Inc.'s average 12-month price target has been adjusted to $7.33 from $7.71 by 6 analysts, with forecasts ranging from $2 to $20 per share. This new target suggests a significant 937% potential upside based on the June 18 closing price. The consensus rating for th", "url": "https://www.tradingview.com/news/tradingview:5347e10371092:0-skye-bioscience-inc-stock-12-month-price-target-cut-to-7-33-implies-937-upside/", "source_name": "TradingView", "published_at": "2026-06-19T04:38:53", "published_display": "19 Jun 2026 04:38", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience Inc (SKYE) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Skye Bioscience Inc (SKYE), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. The analysis indicates a current price momentum score of 4.29, with the stock trading bet", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-skye/technical", "source_name": "TradingKey", "published_at": "2026-06-19T01:39:16", "published_display": "19 Jun 2026 01:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience Inc (SKYE) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Skye Bioscience Inc's (SKYE) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split events. The current stock price and market capitalization a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-skye/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T23:38:53", "published_display": "18 Jun 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Cuts Target Price to $6", "summary": "Piper Sandler has reiterated its Buy rating for SKYE BIOSCIENCE INC (SKYE.US) but has adjusted its price target downwards to $6. This revision indicates that while the firm still sees potential for the company, its valuation estimates have been moderated.", "url": "https://news.futunn.com/en/post/72946177/piper-sandler-maintains-skye-bioscience-inc-skyeus-with-buy-rating", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-14T19:40:34", "published_display": "14 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience, Inc. Amends Articles of Incorporation to Increase Authorized Shares \u2013 SEC 8-K Filing May 2026", "summary": "Skye Bioscience, Inc. has amended its Articles of Incorporation to increase its authorized common shares from 100 million to 300 million, a change approved by shareholders on May 26, 2026. This move provides the company with greater flexibility for future capital raising, acquisi", "url": "https://www.minichart.com.sg/2026/05/31/skye-bioscience-inc-amends-articles-of-incorporation-to-increase-authorized-shares-sec-8-k-filing-may-2026/", "source_name": "Minichart", "published_at": "2026-05-31T10:09:24", "published_display": "31 May 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SKYE - Skye Bioscience Inc Stock Price and Quote", "summary": "This article provides a detailed overview of Skye Bioscience Inc. (SKYE) stock, including its latest financial data, key metrics, analyst ratings, and a chronological list of recent news and press releases. It also includes information about the company's executive team and recen", "url": "https://finviz.com/stock?t=SKYE", "source_name": "Finviz", "published_at": "2026-05-30T17:11:36", "published_display": "30 May 2026 17:11", "sentiment": "negative", "sentiment_pct": 41, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience (NASDAQ: SKYE) holders back major share authorization increase", "summary": "Skye Bioscience's stockholders have approved an amendment to the company's charter, tripling the authorized common shares from 100 million to 300 million. This change, which does not affect current outstanding shares, allows the company more flexibility for future issuances. The ", "url": "https://www.stocktitan.net/sec-filings/SKYE/8-k-skye-bioscience-inc-reports-material-event-6a6adbfa6492.html", "source_name": "Stock Titan", "published_at": "2026-05-29T20:38:56", "published_display": "29 May 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SKYE: All proposals passed, directors elected, and no stakeholder questions were raised", "summary": "Skye Bioscience, Inc.'s 2026 Annual General Meeting successfully passed all proposals, including the election of directors, auditor ratification, an increase in authorized shares, and executive compensation. The meeting also established a quorum and concluded without any question", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3394210:0-skye-all-proposals-passed-directors-elected-and-no-stakeholder-questions-were-raised/", "source_name": "TradingView", "published_at": "2026-05-26T17:09:42", "published_display": "26 May 2026 17:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye announces cohort review committee approved opening of cohort 2 based on favorable safety data from first four participants treated in cohort 1", "summary": "Skye Bioscience, Inc. announced that its cohort review committee has approved the opening of cohort 2 for its clinical trial. This decision was made based on favorable safety data observed in the first four participants treated in cohort 1. The company is actively developing next", "url": "https://www.marketscreener.com/news/skye-announces-cohort-review-committee-approved-opening-of-cohort-2-based-on-favorable-safety-data-f-ce7f5ad9d980f521", "source_name": "marketscreener.com", "published_at": "2026-05-20T11:28:13", "published_display": "20 May 2026 11:28", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience gets approval to open second cohort in study", "summary": "Skye Bioscience, Inc. has received approval to open the second cohort of its CBeyond Part C Expansion Study, following a safety review of the first cohort. The study is evaluating nimacimab monotherapy at varying doses for obesity and metabolic health disorders. Investors have re", "url": "https://www.investing.com/news/company-news/skye-bioscience-gets-approval-to-open-second-cohort-in-study-93CH-4700961", "source_name": "Investing.com", "published_at": "2026-05-20T11:19:13", "published_display": "20 May 2026 11:19", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Announces Cohort Review Committee Approved Opening of", "summary": "Skye Bioscience, a clinical-stage biotechnology company, announced that its Cohort Review Committee (CRC) has approved the opening of Cohort 2 for the CBeyond Part C Expansion Study. This decision was based on favorable safety data from the first four participants in Cohort 1, wh", "url": "https://www.globenewswire.com/news-release/2026/05/20/3298335/0/en/skye-announces-cohort-review-committee-approved-opening-of-cohort-2-based-on-favorable-safety-data-from-first-four-participants-treated-in-cohort-1.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T10:40:54", "published_display": "20 May 2026 10:40", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience Faces Nasdaq Compliance Risk Over Equity", "summary": "Skye Bioscience (SKYE) has received a notice from Nasdaq stating that the company is out of compliance with the Nasdaq Global Market\u2019s minimum $10 million stockholders\u2019 equity requirement, having reported only $9,011,804. The company has until June 29, 2026, to submit a plan to r", "url": "https://www.theglobeandmail.com/investing/markets/stocks/SKYE-Q/pressreleases/1979451/skye-bioscience-faces-nasdaq-compliance-risk-over-equity/", "source_name": "The Globe and Mail", "published_at": "2026-05-17T00:09:35", "published_display": "17 May 2026 00:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience stock price target cut to $6 by Piper Sandler on cash runway", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOMk5NYVYtenlVTzZ3X3BXS3NJLV8tVW1Uc1FqdTl1eEFKRFhIVkxNel9OZV9BQ1p6UTEyaldjN0ZOaElPbTJQSk1IR256NDZYMkZFOWgxVFJMOFhFX05hSXdYMVJIYVZ0VVR6S0MxcUotVTR1elFYZDRVZUZLa3JkRTlvWXVwR0dKWFlic2M5dTI3LWhmLVVIZ0dtdHA0ajVHYXdhNHBnZW84NXl1OS14X05NOWt5WnFMLWRrOU5VYXdYa2hWajRmdDR3ZThVdHdk?oc=5", "source_name": "Investing.com", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 19, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Skye Bioscience (NASDAQ:SKYE) Must Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Skye Bioscience Stock Plummet A Whopping 60% Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxNSk1KNmVBODJfb18yb3gzQVktX0tDclNJak5CaEJvNEMyMklOVzZlVnlYT3c2cGNZRHZCaGlFSVZJZzY3dHZDZDlYNVJIU1ByUTdVTGtRamMtNWZaQk9vTXZtU3NNTUZGV1huaXkwYmNBeWhhM1JGck8xd2xZajRwZHIxRENPM2Mxc1YwNVFobEtXZkhNSmoxaFpzbVF0RzFUcmZFREotcTZyTkwwbjVCb1VkZEtuQkloOG90QU9ILXdsaXo5TzU4MUVxV1UySHRiRXFETW1md05mZ3pLMWpfZmhfV2F5cXZFZVRwZ2hqMUI?oc=5", "source_name": "Stocktwits", "published_at": "2025-10-06T11:56:54+00:00", "published_display": "06 Oct 2025 11:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After losing 27% in the past year, Skye Bioscience, Inc. (NASDAQ:SKYE) institutional owners must be relieved by the recent gain", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-24T07:00:00+00:00", "published_display": "24 Jul 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ex-B.C. stock promoter Avtar Dhillon sentenced to prison for fraud in U.S.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPYXFPeXFWcWxLWHRBb3A2OE9MdU9DdnhtWi1Wd24ydjRkVEljcTllUjdfTUtnVlA0eGM2eXdOVmpuQVVTcVFEeEc5ZGVTb0tUdjR4TE5QYTVtLUZ6VzVlMksybzNCR25IOFdYT1FNYmdrR2xfQlQyQlBwZTNRMl9kSVZzbGV2bXE1bEt6YzZCMGNudURpVUdUcVZYR1BRSS1aV0ZGNlNNTWFLOGRjeV9DaU1Cb0FiRFR6M0VhZHFMN2RxQQ?oc=5", "source_name": "Vancouver Is Awesome", "published_at": "2024-12-05T08:00:00+00:00", "published_display": "05 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience (SKYE) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE0tcHE2ZTRjZ1g5OE1oRkFQZWhRMW82a1pvN2hQMXZSbkp2aXVNc09aMjk1NDVhZFRNUWVya0tzMUJhTXJXNzkxd2EtWEVfQWN5WENGeWN1bUVNdw?oc=5", "source_name": "MarketBeat", "published_at": "2024-04-12T18:11:34+00:00", "published_display": "12 Apr 2024 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience (SKYE) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE5hMzFHaEZ5MVJISHRyaHh3ZVZqMHhaMm9hczRSTUdUVHNZZWlZNzlzZjZBdmkwbG9uQVhGRkk2bW03RlJXUlk3RHM0bXpqUQ?oc=5", "source_name": "Stock Titan", "published_at": "2021-04-24T00:02:03+00:00", "published_display": "24 Apr 2021 00:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AYTU Stock Price and Chart \u2014 NASDAQ:AYTU", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5ac3hWaFkwcU91UFNDbzE1NlRFUHlmVDNqSXl3X2VRYmdDeDJ1WFd3VkNlX25JM2ttZmhzb3NmZjM5OGMtdFBlZG5VT0cxSFpwTFJyQVd4Q1Buam81?oc=5", "source_name": "TradingView", "published_at": "2017-10-21T02:34:37+00:00", "published_display": "21 Oct 2017 02:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TXMD Stock Price and Chart \u2014 NASDAQ:TXMD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5HTzJmbkZsNFVmTUMtanBCdUxvcm1fS3UzTzJ1U0l6U3RwTi0wdnFCTWlhTTltZjFna3dtbnpBVE5fTURlVERTRzRLOW1XMTNXR2hXbzR2eU9ZWDVC?oc=5", "source_name": "TradingView", "published_at": "2017-10-10T22:58:51+00:00", "published_display": "10 Oct 2017 22:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-16T05:52:27+00:00", "published_display": "16 Jul 2026 05:52", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience, Inc. Financial Disclosures & SEC Filings", "summary": "This page provides a comprehensive list of Skye Bioscience, Inc.'s SEC filings and other crucial corporate documents, including annual and quarterly reports, earnings releases, and corporate presentations. These documents outline the company's financial performance, operational u", "url": "https://www.tradingview.com/symbols/BOATS-SKYE/documents/", "source_name": "TradingView", "published_at": "2026-07-01T13:42:07", "published_display": "01 Jul 2026 13:42", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Skye Bioscience, Inc. (NASDAQ: SKYE) on behalf of investors who purchased securities before November 4, 2024, and still hold them. The investigation seeks to determine if Skye and its officers engaged in", "url": "https://natlawreview.com/press-releases/skye-bioscience-inc-skye-investigation-bronstein-gewirtz-grossman-llc-1", "source_name": "The National Law Review", "published_at": "2026-06-30T18:39:43", "published_display": "30 Jun 2026 18:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Skye Bioscience, Inc. \u2013 NASDAQ:SKYE", "summary": "This article provides financial information for Skye Bioscience, Inc. (NASDAQ: SKYE), specifically focusing on its forward price-to-sales ratio. The content appears to be a market data page from TradingView, offering an overview of the company's financials for investors and analy", "url": "https://www.tradingview.com/symbols/NASDAQ-SKYE/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T19:09:45", "published_display": "27 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Skye Bioscience, Inc. \u2013 NASDAQ:SKYE", "summary": "This article provides the \"Price to earnings forward\" metric for Skye Bioscience, Inc. (NASDAQ: SKYE) as displayed on TradingView. It notes that the market is closed and no trades have occurred for this specific metric. The content primarily consists of navigation and disclaimer ", "url": "https://www.tradingview.com/symbols/NASDAQ-SKYE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:40:18", "published_display": "27 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Skye Bioscience, Inc. \u2013 NASDAQ:SKYE", "summary": "This article provides financial information for Skye Bioscience, Inc. (NASDAQ: SKYE), specifically focusing on its \"Price to book forward\" metric. It appears to be a stub or an incomplete financial data page from TradingView, lacking specific numerical data for the metric but ind", "url": "https://www.tradingview.com/symbols/NASDAQ-SKYE/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:39:46", "published_display": "27 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience, Inc. Actuals & Estimates (FWB:09R)", "summary": "This article provides financial actuals and estimates for Skye Bioscience, Inc. (FWB:09R), covering income statement, balance sheet, cash flow, and valuation metrics. It includes analyst price targets, historical stock performance, earnings reports, and other key financial data. ", "url": "https://www.tradingview.com/symbols/FWB-09R/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T04:11:09", "published_display": "26 Jun 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SKYE Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast for Skye Bioscience, Inc. (SKYE) stock, including analyst price targets, current stock performance, and financial data. It notes that analysts have a max estimated price target of $20.00 and a min of $2.00, while the stock has seen significant decr", "url": "https://www.tradingview.com/symbols/NASDAQ-SKYE/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T15:10:25", "published_display": "25 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience Moves Listing to Nasdaq Capital Market", "summary": "Skye Bioscience (SKYE) has transferred its listing from the Nasdaq Global Market to the Nasdaq Capital Market due to its stockholders' equity falling below the $10 million threshold. The company also faces a compliance issue with Nasdaq's $1.00 minimum bid price rule and has unti", "url": "https://www.theglobeandmail.com/investing/markets/stocks/SKYE/pressreleases/2622086/skye-bioscience-moves-listing-to-nasdaq-capital-market/", "source_name": "The Globe and Mail", "published_at": "2026-06-25T06:09:16", "published_display": "25 Jun 2026 06:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience to Move Listing to Nasdaq Capital Market After Equity Shortfall", "summary": "Skye Bioscience (SKYE) will transfer its common stock listing to the Nasdaq Capital Market, effective June 23, 2026, after its stockholders' equity fell below the Nasdaq Global Market's $10 million requirement. The company reported $9,011,804 in equity as of March 31, 2026. Skye ", "url": "https://www.tradingview.com/news/tradingview:cac6ae3dbb208:0-skye-bioscience-to-move-listing-to-nasdaq-capital-market-after-equity-shortfall/", "source_name": "TradingView", "published_at": "2026-06-23T10:10:25", "published_display": "23 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience (NASDAQ: SKYE) shifts to Nasdaq Capital Market amid listing notices", "summary": "Skye Bioscience is transferring its common stock listing from the Nasdaq Global Market to the Nasdaq Capital Market, effective June 23, 2026, due to non-compliance with the Global Market's minimum stockholders' equity requirement. The company's ticker symbol will remain \"SKYE.\" A", "url": "https://www.stocktitan.net/sec-filings/SKYE/8-k-skye-bioscience-inc-reports-material-event-4999aded00db.html", "source_name": "Stock Titan", "published_at": "2026-06-22T22:10:25", "published_display": "22 Jun 2026 22:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience, Inc. Stock 12\u2011Month Price Target Cut to $7.33, Implies 937% Upside", "summary": "Skye Bioscience, Inc.'s average 12-month price target has been adjusted to $7.33 from $7.71 by 6 analysts, with forecasts ranging from $2 to $20 per share. This new target suggests a significant 937% potential upside based on the June 18 closing price. The consensus rating for th", "url": "https://www.tradingview.com/news/tradingview:5347e10371092:0-skye-bioscience-inc-stock-12-month-price-target-cut-to-7-33-implies-937-upside/", "source_name": "TradingView", "published_at": "2026-06-19T04:38:53", "published_display": "19 Jun 2026 04:38", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience Inc (SKYE) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Skye Bioscience Inc (SKYE), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. The analysis indicates a current price momentum score of 4.29, with the stock trading bet", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-skye/technical", "source_name": "TradingKey", "published_at": "2026-06-19T01:39:16", "published_display": "19 Jun 2026 01:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience Inc (SKYE) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Skye Bioscience Inc's (SKYE) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split events. The current stock price and market capitalization a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-skye/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T23:38:53", "published_display": "18 Jun 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Cuts Target Price to $6", "summary": "Piper Sandler has reiterated its Buy rating for SKYE BIOSCIENCE INC (SKYE.US) but has adjusted its price target downwards to $6. This revision indicates that while the firm still sees potential for the company, its valuation estimates have been moderated.", "url": "https://news.futunn.com/en/post/72946177/piper-sandler-maintains-skye-bioscience-inc-skyeus-with-buy-rating", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-14T19:40:34", "published_display": "14 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience, Inc. Amends Articles of Incorporation to Increase Authorized Shares \u2013 SEC 8-K Filing May 2026", "summary": "Skye Bioscience, Inc. has amended its Articles of Incorporation to increase its authorized common shares from 100 million to 300 million, a change approved by shareholders on May 26, 2026. This move provides the company with greater flexibility for future capital raising, acquisi", "url": "https://www.minichart.com.sg/2026/05/31/skye-bioscience-inc-amends-articles-of-incorporation-to-increase-authorized-shares-sec-8-k-filing-may-2026/", "source_name": "Minichart", "published_at": "2026-05-31T10:09:24", "published_display": "31 May 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SKYE - Skye Bioscience Inc Stock Price and Quote", "summary": "This article provides a detailed overview of Skye Bioscience Inc. (SKYE) stock, including its latest financial data, key metrics, analyst ratings, and a chronological list of recent news and press releases. It also includes information about the company's executive team and recen", "url": "https://finviz.com/stock?t=SKYE", "source_name": "Finviz", "published_at": "2026-05-30T17:11:36", "published_display": "30 May 2026 17:11", "sentiment": "negative", "sentiment_pct": 41, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience (NASDAQ: SKYE) holders back major share authorization increase", "summary": "Skye Bioscience's stockholders have approved an amendment to the company's charter, tripling the authorized common shares from 100 million to 300 million. This change, which does not affect current outstanding shares, allows the company more flexibility for future issuances. The ", "url": "https://www.stocktitan.net/sec-filings/SKYE/8-k-skye-bioscience-inc-reports-material-event-6a6adbfa6492.html", "source_name": "Stock Titan", "published_at": "2026-05-29T20:38:56", "published_display": "29 May 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SKYE: All proposals passed, directors elected, and no stakeholder questions were raised", "summary": "Skye Bioscience, Inc.'s 2026 Annual General Meeting successfully passed all proposals, including the election of directors, auditor ratification, an increase in authorized shares, and executive compensation. The meeting also established a quorum and concluded without any question", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3394210:0-skye-all-proposals-passed-directors-elected-and-no-stakeholder-questions-were-raised/", "source_name": "TradingView", "published_at": "2026-05-26T17:09:42", "published_display": "26 May 2026 17:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye announces cohort review committee approved opening of cohort 2 based on favorable safety data from first four participants treated in cohort 1", "summary": "Skye Bioscience, Inc. announced that its cohort review committee has approved the opening of cohort 2 for its clinical trial. This decision was made based on favorable safety data observed in the first four participants treated in cohort 1. The company is actively developing next", "url": "https://www.marketscreener.com/news/skye-announces-cohort-review-committee-approved-opening-of-cohort-2-based-on-favorable-safety-data-f-ce7f5ad9d980f521", "source_name": "marketscreener.com", "published_at": "2026-05-20T11:28:13", "published_display": "20 May 2026 11:28", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience gets approval to open second cohort in study", "summary": "Skye Bioscience, Inc. has received approval to open the second cohort of its CBeyond Part C Expansion Study, following a safety review of the first cohort. The study is evaluating nimacimab monotherapy at varying doses for obesity and metabolic health disorders. Investors have re", "url": "https://www.investing.com/news/company-news/skye-bioscience-gets-approval-to-open-second-cohort-in-study-93CH-4700961", "source_name": "Investing.com", "published_at": "2026-05-20T11:19:13", "published_display": "20 May 2026 11:19", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Announces Cohort Review Committee Approved Opening of", "summary": "Skye Bioscience, a clinical-stage biotechnology company, announced that its Cohort Review Committee (CRC) has approved the opening of Cohort 2 for the CBeyond Part C Expansion Study. This decision was based on favorable safety data from the first four participants in Cohort 1, wh", "url": "https://www.globenewswire.com/news-release/2026/05/20/3298335/0/en/skye-announces-cohort-review-committee-approved-opening-of-cohort-2-based-on-favorable-safety-data-from-first-four-participants-treated-in-cohort-1.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T10:40:54", "published_display": "20 May 2026 10:40", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience Faces Nasdaq Compliance Risk Over Equity", "summary": "Skye Bioscience (SKYE) has received a notice from Nasdaq stating that the company is out of compliance with the Nasdaq Global Market\u2019s minimum $10 million stockholders\u2019 equity requirement, having reported only $9,011,804. The company has until June 29, 2026, to submit a plan to r", "url": "https://www.theglobeandmail.com/investing/markets/stocks/SKYE-Q/pressreleases/1979451/skye-bioscience-faces-nasdaq-compliance-risk-over-equity/", "source_name": "The Globe and Mail", "published_at": "2026-05-17T00:09:35", "published_display": "17 May 2026 00:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience stock price target cut to $6 by Piper Sandler on cash runway", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOMk5NYVYtenlVTzZ3X3BXS3NJLV8tVW1Uc1FqdTl1eEFKRFhIVkxNel9OZV9BQ1p6UTEyaldjN0ZOaElPbTJQSk1IR256NDZYMkZFOWgxVFJMOFhFX05hSXdYMVJIYVZ0VVR6S0MxcUotVTR1elFYZDRVZUZLa3JkRTlvWXVwR0dKWFlic2M5dTI3LWhmLVVIZ0dtdHA0ajVHYXdhNHBnZW84NXl1OS14X05NOWt5WnFMLWRrOU5VYXdYa2hWajRmdDR3ZThVdHdk?oc=5", "source_name": "Investing.com", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 19, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Skye Bioscience (NASDAQ:SKYE) Must Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPZGhhSUhEb1VXMHhrTlBEN1RuQWJ0aktnaFk0ZFhzMnp1VmJCd0tMVjJ6QU82TDRaUlpoWEdVSDZiNjBjeUdfMU5vWUpEdzBrTDc5eGhHYktwbFlDM0xwZXRDak00NjlYZWFPeEZQdUhkWWFHUVpiTnNjb2lEdUx5Tm5ZTDVUZW9vazltRzgxdUw2MEg4bTEtX3h2UmZwcWZGbTBPTDNoN095ZzB3YzA2cmUtLW1KRXVUZmlZblZENzlsbVN6MEZXREtTNHo0NnVJdGJPUExyV1pRTWFPeENfNWxYVdIB6AFBVV95cUxQbVUzTFEyLTc4dWpLd1Z4dTVUSnRreFkxT1d0clVKQjNYNFduZlpGbXJfMGkzemtfQ3gxNGNwWmVUbVF4ai1zbWZwdE8xamUwV3dRQ1ktUi12aFliaE5teE1DNzlUdnNkMDhRQXVOTkcxOEZFUWhFdEZ0WHRxQ2ljYndVYmdGb2YyYWpaNjk5aWNLWUgwWE5rTWszek1UaXVSdXFTcll4dzZqZHZIaVlqaThxbTU1NGpDd3hYREk3OE1WVG5MYk4wbnBaZzN3WEhuX2l5WFBuRTVxUC1Sb0dLUVFveTBkRGMz?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Skye Bioscience Stock Plummet A Whopping 60% Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxNSk1KNmVBODJfb18yb3gzQVktX0tDclNJak5CaEJvNEMyMklOVzZlVnlYT3c2cGNZRHZCaGlFSVZJZzY3dHZDZDlYNVJIU1ByUTdVTGtRamMtNWZaQk9vTXZtU3NNTUZGV1huaXkwYmNBeWhhM1JGck8xd2xZajRwZHIxRENPM2Mxc1YwNVFobEtXZkhNSmoxaFpzbVF0RzFUcmZFREotcTZyTkwwbjVCb1VkZEtuQkloOG90QU9ILXdsaXo5TzU4MUVxV1UySHRiRXFETW1md05mZ3pLMWpfZmhfV2F5cXZFZVRwZ2hqMUI?oc=5", "source_name": "Stocktwits", "published_at": "2025-10-06T11:56:54+00:00", "published_display": "06 Oct 2025 11:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After losing 27% in the past year, Skye Bioscience, Inc. (NASDAQ:SKYE) institutional owners must be relieved by the recent gain", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-24T07:00:00+00:00", "published_display": "24 Jul 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ex-B.C. stock promoter Avtar Dhillon sentenced to prison for fraud in U.S.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPYXFPeXFWcWxLWHRBb3A2OE9MdU9DdnhtWi1Wd24ydjRkVEljcTllUjdfTUtnVlA0eGM2eXdOVmpuQVVTcVFEeEc5ZGVTb0tUdjR4TE5QYTVtLUZ6VzVlMksybzNCR25IOFdYT1FNYmdrR2xfQlQyQlBwZTNRMl9kSVZzbGV2bXE1bEt6YzZCMGNudURpVUdUcVZYR1BRSS1aV0ZGNlNNTWFLOGRjeV9DaU1Cb0FiRFR6M0VhZHFMN2RxQQ?oc=5", "source_name": "Vancouver Is Awesome", "published_at": "2024-12-05T08:00:00+00:00", "published_display": "05 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience (SKYE) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE0tcHE2ZTRjZ1g5OE1oRkFQZWhRMW82a1pvN2hQMXZSbkp2aXVNc09aMjk1NDVhZFRNUWVya0tzMUJhTXJXNzkxd2EtWEVfQWN5WENGeWN1bUVNdw?oc=5", "source_name": "MarketBeat", "published_at": "2024-04-12T18:11:34+00:00", "published_display": "12 Apr 2024 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skye Bioscience (SKYE) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE5hMzFHaEZ5MVJISHRyaHh3ZVZqMHhaMm9hczRSTUdUVHNZZWlZNzlzZjZBdmkwbG9uQVhGRkk2bW03RlJXUlk3RHM0bXpqUQ?oc=5", "source_name": "Stock Titan", "published_at": "2021-04-24T00:02:03+00:00", "published_display": "24 Apr 2021 00:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AYTU Stock Price and Chart \u2014 NASDAQ:AYTU", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5ac3hWaFkwcU91UFNDbzE1NlRFUHlmVDNqSXl3X2VRYmdDeDJ1WFd3VkNlX25JM2ttZmhzb3NmZjM5OGMtdFBlZG5VT0cxSFpwTFJyQVd4Q1Buam81?oc=5", "source_name": "TradingView", "published_at": "2017-10-21T02:34:37+00:00", "published_display": "21 Oct 2017 02:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TXMD Stock Price and Chart \u2014 NASDAQ:TXMD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5HTzJmbkZsNFVmTUMtanBCdUxvcm1fS3UzTzJ1U0l6U3RwTi0wdnFCTWlhTTltZjFna3dtbnpBVE5fTURlVERTRzRLOW1XMTNXR2hXbzR2eU9ZWDVC?oc=5", "source_name": "TradingView", "published_at": "2017-10-10T22:58:51+00:00", "published_display": "10 Oct 2017 22:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 51, "sentiment_summary": {"positive": 12, "negative": 10, "neutral": 29, "score": 51, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 13.55, "count": 24}, {"event": "earnings", "label": "Earnings", "weight": 8.6, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 0.69, "latest_week": "2026-07-10", "one_week_move": -1.5, "four_week_move": -12.3, "twelve_week_move": -12.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.687727, "market_dynamics_buy_signal": false, "relative_strength": -64.591387, "fair_value_gap": -82.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 47.9964, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.5% over one week, -12.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 58, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 13}, {"label": "Market source", "count": 6}, {"label": "simplywall.st", "count": 4}, {"label": "The Globe and Mail", "count": 3}, {"label": "Stock Titan", "count": 3}, {"label": "Stocktwits", "count": 2}, {"label": "TradingKey", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 24}, {"label": "Earnings", "count": 17}, {"label": "Analyst action", "count": 5}, {"label": "Regulatory and legal", "count": 3}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.5% over one week, -12.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?"}], "updated_at": "2026-07-17T05:00:24.700979+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}